This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

About ATTR-CMAbout
ATTR-CMDisease ImpactWhen to Rule Out ATTR-CMDiagnosing ATTR-CMAbout VYNDAMAXAbout
VYNDAMAXMortality and Hospitalization6MWT/KCCQ-OS5-year DataHow VYNDAMAX WorksSafety Profile Study DesignDosingAccess & SupportAccess & SupportAccessing VYNDAMAXVyndaLinkResourcesResourcesEventsMaterialsVideos
Prescribing InformationPatient InformationIndication Patient Site
VyndaLink
When you’ve decided VYNDAMAX is appropriate for your patient, VyndaLink* can help
Before Treatment

Connect eligible patients with financial assistance resources

Conduct a benefits verification to determine your patient’s coverage for VYNDAMAX and VYNDAQEL® (tafamidis meglumine), including out-of-pocket costs

Identify payer requirements for VYNDAMAX and provide information about the prior authorization process as needed†

Identify specialty pharmacy options based on your patient’s insurance coverage.
VYNDAMAX is available through multiple specialty pharmacies

VyndaLink can help connect your patients with financial assistance resourcesMedicare/Government-Insured Patients
  • For those patients who need help with their medication cost-sharing requirements, VyndaLink can refer patients who may be eligible to Medicare Extra Help or alternate sources of funding
  • If support through an alternate funding source is not available, some patients may be eligible to receive VYNDAMAX at no cost through the Pfizer Patient Assistance Program.‡ Patients must reapply annually
Criteria depend on a number of factors, including the specific medicines prescribed, insurance status, and household size and income. The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions. Patients must meet eligibility requirements and reapply as needed.Eligible Commercially Insured Patients
  • Eligible commercially-insured patients may pay as little as $0 per month through the VYNDAMAX Co-pay Savings Program§
Limits, terms, and conditions apply.Uninsured Patients
  • VyndaLink will check if your patient may appear eligible for Medicaid and can tell them how to contact Medicaid to apply
  • VyndaLink may be able to help your eligible uninsured patients receive VYNDAMAX while applying for Medicaid, for up to 90 days, through the Pfizer Patient Assistance Program||
  • If your patients do not qualify for Medicaid, they may be able to get up to a 1-year free supply of VYNDAMAX through the Pfizer Patient Assistance Program||
Criteria depend on a number of factors, including the specific medicines prescribed, insurance status, and household size and income. The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions. Patients must meet eligibility requirements and reapply as needed.Title
Call VyndaLink at 1-888-222-8475 Monday-Friday, 8 AM-8 PM ET or
go to www.VyndaLink.com
Next: Learn about VYNDAMAX access and coverage ContinueLoadingSee www.VyndaLinkPortal.com for details.The same VyndaLink support offerings available to patients prescribed VYNDAMAX are also available to patients prescribed VYNDAQEL.Please note where a PA is required, the physician must submit required information directly to the patient’s insurer.PA=prior authorization.Access & SupportVyndaLink.com has more information about support services for you and your patients View VyndaLinkLoading
Access resources for you and your patient Explore resources Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-VDM-USA-1664
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-VDM-USA-0908
INDICATION AND LIMITATIONS OF USE VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.Please see Full Prescribing Information including Patient Information.
Important Safety InformationAdverse Reactions
In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

Specific Populations

Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.IndicationVYNDAQEL® (tafamidis meglumine) and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Please see Full Prescribing Information including Patient Information.